Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 933-936

  Kempton, Christine L ^a   Allen, Geoff ^b   Hord, Jeffrey ^c   Kruse Jarres, Rebecca ^d   Pruthi, Rajiv K ^e   Walsh, Christopher ^f   Young, Guy ^g   Soucie, J Michael ^h  

^a EMORY UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c AKRON CHILDREN'S HOSPITAL   (United States)

^d TULANE UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; PREDNISONE; RITUXIMAB;

ADULT; ANTIBODY TITER; BLOOD CLOTTING; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; HAZARD RATIO; HEMOPHILIA; HEMOPHILIA A; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; LETTER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CASE-CONTROL STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; LIKELIHOOD FUNCTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84865355228     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23269     Document Type: Letter

References (11)

1. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-1054.
2. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
3. Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: A systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-912.
4. Kempton CL, Soucie JM, Miller CH, et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8: 2224-2231.
5. Robbins D, Kulkarni R, Gera R, et al. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68: 184-188.
6. Puetz JJ, Bouhasin JD. High-titre factor VIII inhibitor in two children with mild haemophilia A. Haemophilia 2001; 7: 215-219.
7. Franchini M, Girelli D, Olivieri O, et al. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patientswith mild/moderate haemophilia A. Haemophilia 2006; 12: 448-451.
8. Santagostino E, Gringeri A, Tagliavacca L, et al. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995; 74: 619-621.
9. White GCII, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
10. Bagnall RD, Giannelli F, Green PM. Int22h-related inversions causing hemophilia A: A novel insight into their origin and a new more discriminant PCR test for their detection. J Thromb Haemost 2006; 4: 591-598.
11. Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics 2001; 57: 114-119.